An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory
O. Haabeth, J. Lohmeyer, A. Sallets, T. Blake, I. Sagiv-Barfi, D. Czerwinski, B. McCarthy, A. E. Powell, P. A. Wender, R. M. Waymouth, R. Levy
This paper develops an mRNA SARS-CoV-2 vaccine using CARTs with a TLR-9 agonist, showing it induces neutralizing antibodies and T cell memory in mice.
bioRxiv · Apr 14, 2021Immunology